Published in J Clin Invest on August 01, 1993
Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest (1999) 3.32
Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest (1999) 2.03
T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J Exp Med (1999) 1.85
Tregs and allergic disease. J Clin Invest (2004) 1.64
CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest (2000) 1.43
IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression. Immunology (1997) 1.37
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 1.29
Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol (2012) 1.18
Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. J Exp Med (2006) 1.10
Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov (2009) 1.10
T-cell subset regulation in atopy. Curr Allergy Asthma Rep (2011) 1.09
Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med (1995) 1.08
Update in the mechanisms of allergen-specific immunotheraphy. Allergy Asthma Immunol Res (2010) 1.07
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Tracking antigen-specific T-cells during clinical tolerance induction in humans. PLoS One (2010) 0.99
T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol (2010) 0.94
Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. Chest (2012) 0.88
Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child (2004) 0.85
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy (2010) 0.85
Immunotherapy with allergen peptides. Allergy Asthma Clin Immunol (2007) 0.83
Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. Mediators Inflamm (2003) 0.80
Strategies to query and display allergy-derived epitope data from the immune epitope database. Int Arch Allergy Immunol (2012) 0.80
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology (2001) 0.79
Allergen-specific subcutaneous immunotherapy in allergic asthma: immunologic mechanisms and improvement. Libyan J Med (2010) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Immunological markers in allergic rhinitis patients treated with date palm immunotherapy. Inflamm Res (2012) 0.77
Essential Contribution of CD4+ T Cells to Antigen-Induced Nasal Hyperresponsiveness in Experimental Allergic Rhinitis. PLoS One (2016) 0.76
Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76
Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2015) 0.76
Actual therapeutic management of allergic and hyperreactive nasal disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg (2004) 0.75
Venom immunotherapy modulates interleukin-4 and interferon-gamma messenger RNA expression of peripheral T lymphocytes. Immunology (1996) 0.75
Effectiveness of allergy immunotherapy for asthma. West J Med (1995) 0.75
Nature of regulatory T cells in the context of allergic disease. Allergy Asthma Clin Immunol (2008) 0.75
New insights into the mechanisms of immunotherapy. Eur Arch Otorhinolaryngol (1995) 0.75
Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol (2016) 0.75
Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature (1989) 5.10
Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature (1989) 3.15
Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet (1978) 2.51
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol (1988) 2.00
Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med (1992) 1.88
Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med (1991) 1.77
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med (1980) 1.40
Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol (1991) 1.38
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol (1991) 1.37
A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies. Ann Intern Med (1971) 1.27
Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol (1991) 1.24
Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis (1992) 1.17
The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol (1988) 1.15
Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun (1989) 1.11
UCHL1+ (CD45RO+) 'memory' T cells predominate in the CD4+ cellular infiltrate associated with allergen-induced late-phase skin reactions in atopic subjects. Clin Exp Immunol (1991) 1.08
Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy (1988) 1.03
Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach. Eur J Pharmacol (1992) 1.02
Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol (1991) 1.02
Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones. Clin Exp Allergy (1991) 1.01
Immunotherapy. Prog Allergy (1982) 0.95
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol (1985) 0.92
The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy (1985) 0.91
Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy (1991) 0.89
The pattern of human late-phase skin reactions to extracts of aeroallergens. J Allergy Clin Immunol (1988) 0.86
Co-expression of CD25 and CD3 in atopic allergy and asthma. Immunology (1992) 0.85
Reduction of increased serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy. Clin Exp Allergy (1989) 0.85
Induction of antigen-specific suppressor cells in patients with hay fever receiving immunotherapy. J Allergy Clin Immunol (1985) 0.84
The relationship between anti-IgE auto-antibodies and the IgE response to wasp venom during immunotherapy. Clin Exp Allergy (1990) 0.83
Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy (1989) 0.82
The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects. Clin Exp Allergy (1992) 0.81
What can we learn from studies of lymphocytes present in allergic-reaction sites? J Allergy Clin Immunol (1992) 0.81
Allergic rhinitis to ragweed pollen. I. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol (1992) 0.79
Immune mechanisms in allergen-specific immunotherapy. Clin Immunol Immunopathol (1989) 0.79
Suppression of the late cutaneous response by immunotherapy. J Allergy Clin Immunol (1989) 0.78
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis (1980) 8.40
Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest (1991) 3.88
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis (1990) 3.70
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med (1995) 3.61
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis (1988) 3.45
HPV-16-related DNA sequences in Kaposi's sarcoma. Lancet (1992) 3.09
Studies on eosinophil leucocyte migration. II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin Exp Immunol (1970) 3.09
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis (1989) 3.06
Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J (2004) 3.04
T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol (1996) 2.92
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol (1991) 2.88
Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (2007) 2.77
Standards for practical allergen-specific immunotherapy. Allergy (2006) 2.70
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy (2005) 2.55
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
T cells and eosinophils in the pathogenesis of asthma. Immunol Today (1992) 2.30
Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol (1997) 2.28
CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis (1990) 2.18
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy (1985) 2.15
Studies on eosinophil leucocyte migration. I. Eosinophil and neutrophil accumulation following antigen-antibody reactions in guinea-pig skin. Clin Exp Immunol (1970) 2.13
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med (1998) 2.12
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol (1993) 2.11
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet (1992) 2.06
Leucoattractants enhance complement receptors on human phagocytic cells. Clin Exp Immunol (1979) 2.04
The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol (1988) 2.00
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med (1996) 1.93
Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology (1992) 1.93
IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology (1990) 1.85
Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products. Clin Exp Immunol (1982) 1.84
Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis (1991) 1.84
Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med (1995) 1.83
T lymphocyte activation in acute severe asthma. Lancet (1988) 1.81
Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma. J Clin Invest (1982) 1.77
IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol (2000) 1.75
Acute exposure to diesel exhaust increases IL-8 and GRO-alpha production in healthy human airways. Am J Respir Crit Care Med (2000) 1.75
Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) (1981) 1.75
BSACI guidelines for the management of drug allergy. Clin Exp Allergy (2009) 1.74
Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol (1997) 1.73
Different airway inflammatory responses in asthmatic and healthy humans exposed to diesel. Eur Respir J (2004) 1.71
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
The identification of fibrinopeptide B as a chemotactic agent derived from human fibrinogen. Br J Haematol (1974) 1.70
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol (1997) 1.69
Frequent exacerbators--a distinct phenotype of severe asthma. Clin Exp Allergy (2014) 1.69
Eosinophils 1992. Immunol Today (1992) 1.69
Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet (1999) 1.69
Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis (1992) 1.68
A multicenter study on the use of pulsed low-intensity direct current for healing chronic stage II and stage III decubitus ulcers. Arch Dermatol (1993) 1.68
Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol (1991) 1.67
The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol (1988) 1.67
The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today (1999) 1.67
Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol (1993) 1.67
Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol (2001) 1.67
Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med (1996) 1.66
Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med (1997) 1.64
Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med (1996) 1.64
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64